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Chimeric rodent malaria parasites with the endogenous circumsporozoite protein (csp) gene
replaced with csp from the human parasites Plasmodium falciparum (Pf) and P. vivax (Pv) are
used in preclinical evaluation of CSP vaccines. Chimeric rodent parasites expressing PfCSP
have also been assessed as whole sporozoite (WSP) vaccines. Comparable chimeric P.
falciparum parasites expressing CSP of P. vivax could be used both for clinical evaluation of
vaccines targeting PvCSP in controlled human P. falciparum infections and in WSP vaccines
targetingP. vivax andP. falciparum.Wegenerated chimericP. falciparumparasites expressing
both PfCSP and PvCSP. ThesePf-PvCSP parasites produced sporozoite comparable to wild
type P. falciparum parasites and expressed PfCSP and PvCSP on the sporozoite surface. Pf-
PvCSPsporozoites infectedhumanhepatocytesand inducedantibodies to the repeatsof both
PfCSP and PvCSP after immunization of mice. These results support the use of Pf-PvCSP
sporozoites in studies optimizing vaccines targeting PvCSP.
Keywords: malaria, Plasmodium falciparum, Plasmodium vivax, circumsporozoite protein (CSP), chimeric
parasites, vaccinesINTRODUCTION
Plasmodium falciparum (Pf) and P. vivax (Pv) are two major human malaria parasites that threaten
public health, mainly in tropical areas. Malaria parasites are transmitted by Anopheles mosquitoes
where they develop into infectious sporozoites that reside in the salivary glands. After a bite of an
infected mosquito, sporozoites enter the blood stream of the mammalian host and migrate to thegy | www.frontiersin.org December 2020 | Volume 10 | Article 5910461
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replicate to form thousands of daughter merozoites, which are
released into the blood and invade erythrocytes. The pre-
erythrocytic stages of Plasmodium parasites, i.e. sporozoites
and liver stages, are attractive targets of leading malaria
vaccine candidates, including RTS,S, the most advanced
subunit vaccine against P. falciparum tested in Phase III
clinical trials (Kester et al., 2009; Cohen et al., 2010; Agnandji
et al., 2012; Olotu et al., 2016). RTS,S is based on the
circumsporozoite protein (CSP), a major surface protein
expressed by Plasmodium sporozoites and early liver stages
which plays a critical role in sporozoite formation, invasion of
mosquito salivary glands and invasion of host hepatocytes
(Ménard, 2000; Sinnis and Coppi, 2007; Coppi et al., 2011).
This protein contains a highly conserved central repeat region
flanked by N- and C -terminal regions. B-cell responses to PfCSP
target predominantly the protein’s central NANP repeat region,
generating antibodies capable of protecting animal models from
Plasmodium infection and NANP antibodies induced by RTS,S
immunization are associated with clinical protection (White
et al., 2013; Foquet et al., 2014; Sack et al., 2014; Triller et al.,
2017). CSP from P. vivax also contains an immunogenic central
repeat region with two major PvCSP alleles, VK210 and VK247
considered as important targets for a vaccine (Yadava and
Waters, 2017). So far pre-erythrocytic subunit vaccines targeting
CSP, including RTS,S, have shown low to modest protective
efficacy in clinical trials and in field studies (Agnandji et al.,
2015; Hoffman et al., 2015; Clemens and Moorthy, 2016; Long
and Zavala, 2016; Olotu et al., 2016; Healer et al., 2017;Mahmoudi
andKeshavarz, 2017) emphasizing the need to improveCSP-based
vaccination approaches which requires efficient preclinical and
clinical evaluation of different vaccines. Clinical evaluation of P.
falciparum vaccines is greatly aided by the ability to vaccinate
individuals and then examine vaccine efficacy in controlled human
malaria infections (CHMI) (Sauerwein et al., 2011; Spring et al.,
2014; Bijker et al., 2016; Stanisic et al., 2018). Although CHMI for
P. vivax has been developed (Arévalo-Herrera et al., 2016; Bennett
et al., 2016; Payne et al., 2017; Hall et al., 2019), the lack of a
continuous in vitro culture system for P. vivax blood stages limits
the availability ofP. vivax sporozoites for clinical human infections.
In addition, since P. vivax forms dormant hypnozoites in the liver,
which can causing infection relapses, safe and effective means for
clearance of hypnozoites are essential for P. vivax CHMI studies
(Payne et al., 2017).
In multiple preclinical studies, the evaluation of the efficacy of
CSP-based vaccines and anti-CSP antibodies has been performed
using chimeric rodent malaria parasites expressing CSP from
either P. falciparum or P. vivax (Espinosa et al., 2013; Gimenez
et al., 2017; Salman et al., 2017; Vijayan et al., 2017; de Camargo
et al., 2018; Marques et al., 2020). The availability of comparable
chimeric P. falciparum parasites expressing PvCSP would permit
the analysis of protective efficacy of PvCSP-based vaccines in
clinical studies using P. falciparum-based CHMI, bypassing the
need for P. vivax sporozoite production and hypnozoite
elimination. However, in contrast to efficient PvCSP expression
and sporozoite production in chimeric rodent parasites, we foundFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2that chimeric P. falciparum lines with the PfCSP gene replaced by
PvCSP, failed to produce salivary gland sporozoites, indicating that
PvCSP cannot fully complement the role of PfCSP in P. falciparum
sporozoite formation (Marin-Mogollon et al., 2018). To develop
chimericP. falciparum sporozoites expressingPvCSP,we therefore
aimed at generating a chimeric P. falciparum line expressing both
the endogenous PfCSP and an engineered PvCSP. It has been
shown that introducing the P. falciparum csp gene as an additional
copy into the genome of the rodent parasite P. berghei (Pb) results
in development of viable and infective sporozoites, expressing both
PbCSP and PfCSP in pre-erythrocytic stages (Mendes et al., 2018a;
Mendes et al., 2018b; Reuling et al., 2020). We used CRISPR/Cas9
gene editing to introduce a chimericPvcsp gene, containing repeats
of both the VK210 and VK247 alleles, into the Pfp47 locus of the
P. falciparum NF54 genome. We found that these Pf-PvCSP
chimeric P. falciparum parasites produced viable, motile
sporozoites expressing both PfCSP and chimeric PvCSP at the
sporozoite surface that are infectious to primary human
hepatocytes. Immunization of mice with these sporozoites
resulted in induction of antibodies against the repeats of both
PfCSP and chimeric PvCSP. These results not only show promise
for the use of Pf-PvCSP sporozoites in clinical CHMI studies for
optimization of vaccines targeting PvCSP, but also suggest that
such chimeric sporozoites can be used in whole, attenuated
sporozoite vaccination approaches, capable of inducing cross-
protective immune responses against both P. falciparum and
P. vivax.MATERIALS AND METHODS
In Vitro Cultivation of P. falciparum Blood
Stages
Wild type P. falciparum NF54 (WT NF54) parasites (Ponnudurai
et al., 1981) were obtained from the Radboud University Medical
Center (Nijmegen, The Netherlands). Parasites were cultured in
RPMI-1640 culture medium supplemented with L-glutamine and
25mM HEPES (Gibco Life Technologies), 50 mg/L hypoxanthine
(Sigma), 0.225% NaHCO3 and 10% human serum at a 5%
hematocrit under 4% O2, 3% CO2 and 93% N2 gas-conditions at
75 rpm at 37°C in a semi-automated culture system (Infers HT
Multitron and Watson Marlow 520U) as previously described
(Mogollon et al., 2016). Fresh human serum and human red
blood cells (RBC) were obtained from the Dutch National Blood
Bank (Sanquin Amsterdam, the Netherlands; permission granted
from donors for the use of blood products for malaria research and
microbiology tested for safety). Production of genetically modified
parasites and characterization of these parasites throughout their
life cycle, including mosquito transmission, was performed under
GMO permits IG 17-230_II-k and IG 17-135_III.
Laboratory Animals and Ethics Statement
Female C57BL/6Jicomice (6–7weeks; Charles River, NL) were used.
All animal experiments were granted a licence by the Competent
Authority after an advice on the ethical evaluation by the AnimalDecember 2020 | Volume 10 | Article 591046
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experiments were performed in accordance with the Experiments
on Animals Act (Wod, 2014), the applicable legislation in the
Netherlands and in accordance with the European guidelines (EU
directive no. 2010/63/EU) regarding the protection of animals used
for scientific purposes. All experiments were performed in a licenced
establishment for the use of experimental animals (LUMC). Mice
were housed in individually ventilated cages furnished with
autoclaved aspen woodchip, fun tunnel, wood chew block and
nestlets at 21 ± 2°C under a 12:12 h light-dark cycle at a relative
humidity of 55 ± 10%.
Anopheles Rearing
Mosquitoes from a colony of Anopheles stephensi (line Nijmegen
SDA500) were used. Larval stages were reared in water trays at a
temperature of 28 ± 1°C and a relative humidity of 80%. Adult
females were transferred to incubators with a temperature of
28 ± 0.2°C and a relative humidity of 80%. For the transmission
experiments, 3- to 5-day-old mosquitoes were used.Generation of the Chimeric Pf-PvCSP
Parasites
Chimeric P. falciparum parasites expressing both PfCSP and
chimeric PvCSP (PvCSP-chi), were generated using the
previously described pLf0019 construct (Mogollon et al., 2016)
(Figure S1), containing the cas9 gene, together with the gRNA-
donor DNA containing plasmid, pLf0109, targeting Pfp47 which
contains the Pvcsp-chi expression cassette. The pLf0019 construct
contains a blasticidin (bsd) drug-selectable marker cassette and the
pLf0109 gRNA-donor DNA construct contains a hdhfr-yfcu drug-
selectable marker cassette for selection with WR99210 and 5-
fluorocytocine (5-FC)(Figure S1). To generate pLf0109, the
plasmid pLf0047 (Marin-Mogollon et al., 2019), containing two
homology regions and a gRNA expression cassette targeting Pfp47
(PF3D7_1346800), was modified by introducing a Pvcsp-chi
expression cassette, which was commercially synthesized
(Integrated DNA Technologies, Inc.; see Figure S2). This Pvcsp-
chi expression cassette contains a codon-optimized Pvcsp open
reading frame (ORF) containing the N- and C-terminal regions of
the Pvcsp VK210 allele that flank a chimeric repeat sequence
comprising repeats of both the VK210 allele (three times the
repeat GDRADGQPA/GDRAAGQPA) and the VK247 allele
(three times the repeat ANGAGNQPG/ANGAGDQPG). The
ORF of Pvcsp-chi is flanked by EcoRV/EcoRI restriction sites and
cloned into pLf0040 (cut EcoRV/EcoRI) (Marin-Mogollon et al.,
2018) which contains 967bp of the promoter regions of Pfcsp
(PF3D7_0304600) and 917bp of 3’UTR of Pfcsp resulting in
intermediate plasmid T24 (Figure S1). This plasmid was digested
with ApaI/SacII to obtain the complete Pvcsp-chi expression
cassette containing the Pfcsp promoter, the Pvcsp-chi ORF with
the chimeric VK210/VK247 repeats, and the Pfcsp 3’UTR. This
expression cassette was inserted into vector pLf0047 (Figure S1)
using the same restriction enzymes (ApaI/SacII) resulting in the
final construct pLf0109. Plasmids for transfection were isolated
from250ml cultures ofEscherichia coliXL10-GoldUltracompetentFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 3Cells (Stratagene, NL) by maxi-prep (PureYield™ Plasmid
Maxiprep System (Promega, NL) to generate 25–50 µg of DNA
used per transfection. Transfection of WT PfNF54 parasites was
performed using the ‘spontaneous uptake method’ as previously
described (Miyazaki et al., 2020). Briefly uninfected RBC (300 ml of
packed RBCs) were transfected with the constructs pLf0019 and
pLf0109 (a mixture of 25 mg of each circular plasmid in 200 ml
cytomix)using theGenePulserXcell electroporator (BioRad)with a
single pulse (310 V, 950 mF). Subsequently, the transfected RBCs
were washed with complete RPMI1640 medium and mixed with
WT PfNF54 infected RBC (iRBC) with a parasitemia of 0.5% and a
hematocrit of 5%. These cells were transferred into a 10 ml culture
flask and the cultures were maintained under standard conditions
in the semi-automated culture system (Mogollon et al., 2016).
Selection of transfected parasites was performed by applying
double-positive drug pressure from day 3 after transfection using
the drugsWR99210 (2.6 nM) andBSD (5 µg/ml). The positive drug
pressure was maintained until parasites were detectable in thin
blood-smears (at day 15 after transfection). Subsequently, the
parasites were maintained in drug-free medium for 2–4 days until
the parasitemia reached over 10%, followed by applying negative
selection by addition of 5-FC (1 µM) as described before (Mogollon
et al., 2016) in order to eliminate parasites that retained the donor
DNA construct as episomal plasmid and to enrich for the
transfected parasites containing the donor DNA integrated into
the genome. Negative drug pressure in the cultures wasmaintained
until thin blood-smears were parasite-positive (after 7 days). After
the negative selection, iRBC were harvested from cultures for
genotyping by diagnostic PCR and Southern blot analysis.
Subsequently, selected parasites were cloned by limiting dilution
as previously described (Marin-Mogollon et al., 2018). Briefly, serial
dilutions were performed with uninfected RBC in complete
medium (1% hematocrit and 20% serum) and cultured in a total
volumeof100µl incubated in96-well plates, resulting in8 rowswith
the following numbers of iRBCperwell: 100, 10, 5, 2.5, 1.25, 0.6, 0.3,
0.15. Plates were incubated in a Candle Jar at 37°C and culture
medium was changed every other day. Every 5 days RBC were
added resulting in an increase of the hematocrit from 1% to 5%. At
days 10 to 11, samples were collected for thick smear analysis from
the rows with the highest numbers (100 and 10) of iRBC/well. At
day 21 thick smears were made from samples from all rows. Clones
were selected from dilutions/row with less than 40% of the wells
being parasite-positive. These clones were transferred in 10 ml
cultureflasks at 5%hematocrit under standard culture conditions in
the semi-automated culture system for collection of parasites for
further genotype and phenotype analyses (see next section).Genotyping of Pf-PvCSP Parasites
Diagnostic PCR and Southern blot analysis of digested DNA
were performed from material isolated from iRBC obtained from
10 ml cultures, pelleted by centrifugation (1500 g, 5 min). RBC
were then lysed with 5 ml of cold (4°C) erythrocyte lysis buffer
(10× stock solution 1.5 M NH4Cl, 0.1 M KHCO3, 0.01 M
Na2EDTA; pH 7.4; (Janse et al., 2006)) and parasites were
treated with proteinase-K before DNA isolation by standardDecember 2020 | Volume 10 | Article 591046
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construct was analyzed by long-range PCR (LR-PCR) (primers
P1/P3) and standard PCR amplification of the Pvcsp-chi gene
(primers P4/P5), the Pfp47 gene (primers P6/P7) and the
fragment for 5’ integration (5’int; primers P1/P2). The PCR
fragments were amplified using KOD Hot start polymerase
following standard conditions with an annealing temperature
of 52°C for 15 s, 55°C for 15 s, and 63°C for 25 s and an elongation
step of 68°C for 4 min for LR-PCR and with an annealing
temperature of 50°C for 10 s, 55°C for 10 s, and 60°C for 10 s
and an elongation step of 68°C for 1 min for the other PCRs.
Southern blot analysiswas performedwith genomicDNAdigested
with HpaI and EcoRI (4 h at 37°C) to confirm integration of the
replacement of thePfp47 gene by thePvcsp-chi expression cassette.
Digested DNA was hybridized with probes targeting the Pfp47
homology region 1 (HR1), amplified from WT PfNF54 genomic
DNA by PCR using the primers P8/P9 and a second probe
targeting ampicillin (Amp) gene, amplified from plasmid
pLf0109 by PCR using the primers P10/P11.Phenotype analysis Pf-PvCSP parasites: blood
stages, gametocytes, oocysts, and sporozoites
The growth rate of asexual blood stages of the Pf-PvCSP was
determined in 10 ml cultures maintained in the semi-automated
culture system under standard culture conditions. Briefly, a culture
with 0.1% parasitemia was established in complete culturemedium
at a hematocrit of 5%. Medium was changed twice daily and the
culture was maintained for a period of 3 days without refreshing
RBC. For determination of the course of parasitemia, triplicate
samples of 100 µl were collected daily from all cultures and cells
pelleted by centrifugation (9485 g; 30 s) and stainedwithGiemsa.P.
falciparum gametocytes cultures were generated using standard
culture conditions as previously described (Marin-Mogollon et al.,
2018)with somemodifications. Briefly, parasites fromasexual stage
cultures were diluted to a final parasitemia of 0.5%, and cultures
were followed during 14 days without adding new RBC. At day 14,
gametocyte development was analyzed by counting male/female
gametocytes (stage V) in Giemsa stained blood smears. To assess
exflagellation, 20 µl samples of the P. falciparum gametocyte
cultures at day 14 were diluted 1:1 with Fetal Calf Serum (FCS) at
room temperature and exflagellation centers were examined and
quantified 10–20 min after activation in a Bürker cell counter.
For analysis of oocyst and sporozoite production, A. stephensi
mosquitoes were fed when cultures contained mature stage V
gametocytes and showed more than 80 exflagellating parasites
per 105 erythrocytes. Mosquito feeding was performed using the
standard membrane feeding assay (SMFA) (Ponnudurai et al.,
1989). Oocysts were analyzed between day 10 and 12 and salivary
gland sporozoites were counted at day 18 and 21 after feeding.
Oocyst were counted in 10–30 midguts, dissected in a droplet of
mercurochrome (1%) in distilled water on a glass slide. Midguts
were covered with a coverslip and oocyst images were recorded
from dissected midgut in PBS 1 X (100× magnification). For
counting sporozoites, salivary glands from 30–60 mosquitoes
were dissected and homogenized using a grinder in 100 µl ofFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4RPMI pH 7.2 and sporozoites were analyzed in a Bürker cell
counter using phase-contrast microscopy.
Analysis of PvCSP-chi and PfCSP
Expression in Sporozoites
To analyze CSP expression in fixed Pf-PvCSP and WT PfNF54
salivary gland sporozoites by indirect immunofluorescence assay
(IFA), samples of purified salivary gland sporozoites (20 µl) were
placed on a 8-well black cell-line diagnostic microscope slide
(Thermo Scientific, NL), dried for 10 min, and fixed with 4%
paraformaldehyde for 30 min at room temperature. After
fixation the slides were washed three times with PBS and
permeabilized with 20 µl of 0.5% triton in PBS and then
blocked with 10% of FCS in PBS for 1h. Fixed cells were
washed with PBS and incubated overnight at 4°C with the
following monoclonal CSP antibodies: mouse anti-PfCSP (mAb
2A10,MRA-183; 1:200 dilution of 1mg/ml stock solution); mouse
anti-PvCSP VK210 (mAb 2F2; MRA-184; (Salman et al., 2017);
1:200 dilution of 109 µg/ml stock solution) andmouse anti-PvCSP
VK247 (mAb 2E10.E9; MRA-185; (Salman et al., 2017); 1:200
dilution of 125 µg/ml stock solution. Subsequently, cells were
rinsed three times with PBS and incubated with the secondary
antibodies Alexa FLuor®488/594-conjugated chicken anti-mouse
(Invitrogen Detection technologies, NL at 1:500 dilution). Finally,
the cells were washed again three times with PBS and stained with
theDNA-specific dyeHoechst-33342 at a final concentration of 10
µM.Fixed cellswere coveredwith 1–2dropsof an anti-fading agent
(Image-iT™ FX, Life technologies), and a coverslip placed on the
cells and sealed with nail polish. Stained cells were analyzed for
fluorescence using a Leica fluorescence MDR microscope (100×
magnification). Pictures were recorded with a DC500 digital
camera microscope using Leica LAS X software with the
following exposure times: Alexa 488: 1.0 s; Alexa 594: 0.6 s;
Hoechst 0.2 s; bright field 0.62 s (1× gain) or with a Leica SP8
upright confocal microscope.
To analyze CSP expression of live Pf-PvCSP and WT PfNF54
salivary gland sporozoites by indirect immunofluorescence assay
(IFA), samples of 2 × 105 salivary gland sporozoites were
aliquoted in 1.5 ml Eppendorf tubes and were incubated with
the corresponding antibody (mouse anti-PfCSP, mouse anti-
PvCSP VK210 or mouse anti-PvCSPVK247 (1:100 dilution) in
100 µl of 1% (v/v) FCS in PBS 1×, for 1 h on ice. Subsequently,
sporozoites were rinsed with 1.5 ml of 1% (v/v) FCS in PBS and
pelleted by centrifugation at 9300 g for 4 min at 4°C. The
sporozoite pellet was then resuspended in 100 µl 1% FCS in
PBS containing the secondary antibodies; anti–mouse IgG Alexa
488 (1:200) and incubated for 1 h on ice. Sporozoites were rinsed
with 1.5 ml of 1% (v/v) FCS in PBS and pelleted by centrifugation
at 9300 g for 4 min at 4°C, and the resulting pellet was
resuspended in 40 µl of PBS. Of the cell suspension containing
sporozoites 20 µl was placed per well of an 8-well black cell-line
diagnostic microscope slide (Thermo Scientific), incubated
30 min at room temperature (RT), and fixed with 80 µl of 4%
PFA in PBS 1× for 30 min at RT. Finally, the wells were washed
twice with PBS and stained with 10 µMHoechst 33342 in PBS for
15 min at RT. For microscopy analysis, the preparations wereDecember 2020 | Volume 10 | Article 591046
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Life technologies), and a coverslip was placed onto the cells and
sealed with nail polish. Stained cells were analyzed for
fluorescence using a Leica fluorescence MDR microscope
(100× magnification). Pictures were recorded with a DC500
digital camera microscope using Leica LAS X software with the
following exposure times: Alexa 488: 0.7 s; Hoechst 0.136 s;
bright field 0.62 s (1× gain).
Sporozoite Gliding Assay
Sporozoite motility was determined using a sporozoite gliding
assay (Stewart and Vanderberg, 1988; van Schaijk et al., 2008).
Glass slides were placed in a 24 wells plate (Thermofisher, DK)
and coated with an anti-PfCSP monoclonal 3SP2 (courtesy of Dr.
M. McCall, Radboudumc, The Netherlands; 5 mg/ml in PBS)
using 200 µl per slide, and left overnight at RT. The next day
freshly isolated WT PfNF54 and Pf-PvCSP sporozoites, collected
in RPMI (Thermofisher, Gibco 42401-018) with 10% FCS
(Capricornscientific, FBS-12A CP15-1439) at RT were added
to anti-PfCSP coated slides that were washed with PBS. Per slide
30.000 sporozoites were added (in 200 µl RPMI with 10% FCS)
and these glass slides were incubated for 2.5 h at 37°C under 5%
CO2 conditions. Slides were then washed three times with PBS
and fixed with 4% PFA (Thermo Scientific, NL) for 20 min at RT.
Then, the slides were washed three times with PBS and blocked
with 1% BSA (Roche diagnostic, DE) in PBS for 15 min. After
BSA blocking, the slides were washed three times with PBS, and
the primary antibody anti-Pf-3SP2 or anti-PvCSP-VK210 Mab
(mAb 2F2) (10 µg/ml) was added and incubated for 45 min at
RT. Slides were then washed three times with PBS, and incubated
with a secondary antibody goat anti-mouse Alexa fluor 488
(Invitrogen Thermofisher, Oregon, A11001) Mab (diluted 500
times in PBS) for 45 min (RT, in the dark). Finally, slides were
washed three times with PBS in the dark, air dried until the slides
were almost dry and mounted with Coverslips (with Image iT FX
signal Enhancer; Invitrogen Thermofisher, USA) and examined
with a Leica DMR fluorescent microscope with standard GFP
filter for the gliding trails at 63× magnification. The percentage of
gliding was calculated in 8–10 fields, measuring the number of
gliding trails for the WT PfNF54 sporozoites in comparison with
the gliding trails for the Pf-PvCSP sporozoites. The mean and
standard deviation were determined for the percentage of gliding
trail sporozoites.
In Vitro Infection of Primary Human
Hepatocytes by Sporozoites
In vitro primary human hepatocyte maturation assay was
performed as described in (Marin-Mogollon et al., 2019) with
few adaptations. Cryopreserved primary human hepatocytes,
obtained from Xenothech, were thawed according to the
manufacturer and seeded at a density of 60,000 cells/well in a
collagen-coated 96-well clear-bottomed black plate for 2 days.
Medium was refreshed daily (hepatocyte medium: Williams’s E
medium supplemented with 10% heat inactivated fetal bovine
serum, 1% penicillin-streptomycin, 1% fungizone, 0.1 lU/ml
insulin, 70 µM hydrocortisone). Per well, 7 x 104 freshlyFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5dissected Pf-PvCSP and WT PfNF54 sporozoites were added to
the hepatocyte monolayer. After a quick spin (10 min at 1900 g),
the plate was incubated at 37°C under 5% CO2. The medium was
replaced with fresh hepatocyte culture medium 3 h post-
invasion, and daily for 4 days thereafter. Then, hepatocytes
were fixed with ice-cold methanol for at least 10 min on ice. A
standard IFA was performed using an anti-PfHSP70 primary
antibody (StressMarq) with an Alexa fluor 594 (Invitrogen)
secondary antibody and DAPI for nuclear staining. High
content imaging was performed, using the ImageXpress Pico
system (Molecular Devices). Number of parasites, number of
hepatocytes and size of parasites were determined using the CRX
software (Molecular Devices) and data analyzed using the
GraphPad software.Rodent Immunization With Sporozoites
and Antibody Production
For generation of sporozoite-extracts for immunization, salivary
gland sporozoites were isolated as described in the previous
sections. Aliquots of 105 sporozoites in 50 µl PBS were made and
stored at −80°C. After two rounds of freezing and thawing, 105
sporozoites in 200 µl PBS were used to immunize mice by
intravenous injection. Groups of six C57BL/6 mice were
immunized three times with sporozoites at a 7-day interval, and
blood was collected in heparinized capillaries from all mice by
orbital vein puncture 1dayprior to thefirst and third immunization
and one week after the last immunization. Plasma was collected
after centrifugation of the blood samples (1500 g for 8 min at 4°C)
and stored at −20°C until further analysis.
For assessment of anti-CSP antibody titers (total IgG),
enzyme-linked immunosorbent assays (ELISAs) were
performed. High protein-binding capacity 96-well ELISA plates
(Nunc MaxiSorp™ flat-bottom) were coated with synthetic
peptides (Sigma) based on the repeat sequences of PfCSP and
PvCSP. Specifically, plates were coated with peptides with the
amino acid sequence (NANP)4NVDPC for PfCSP, the amino
sequence GD RAD GQP AGD RAA GQP A for the PvCSP
VK210 and the amino sequence ANGAGNQPG ANGAGDQPG
for the PvCSP VK247. The plates were coated overnight at 4°C
with a peptide concentration of 5 µg/ml in PBS with a volume of
50 µl per well. Plates were washed three times with 0.05%
Tween20/BS (PBST) and blocked with 200 µl of PBST with 5%
milk for 30 min at RT. Plates were then washed one additional
time and plasma samples were diluted 1:50 in 1% milk PBST and
a 3-point 1:3 dilution was carried out for each sample. After 3h
incubation at RT, plates were washed three times with PBST and
incubated for 1h at RT with the secondary antibody, horseradish
peroxidase-labelled goat anti-mouse IgG (GE Healthcare UK) at
a dilution of 1:2000. After six PBST washes, the reaction was
developed by adding BD OptEIA™ TMB Substrate Reagent and
incubating for 1 to 5 min at RT, before stopping the reaction by
adding 50 µl Stop solution (2N H2SO4). Absorbance was
immediately measured at 450 nm using a Tecan Infinite M200
plate reader. Data were analyzed in relation to a standard
titration curve of at least 8 points starting a dilution of 1.5u/mlDecember 2020 | Volume 10 | Article 591046
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PfCSP (mAb 2A10, MRA-183); mouse anti-PvCSP VK210 (mAb
2F2; MRA-184) and mouse anti-PvCSP VK247 (mAb 2E10.E9;
MRA-185). All monoclonal antibodies were produced from
hybridoma cell lines obtained from BEI Resources, NIAID, and
kindly provided by Elizabeth Nardin.
Statistics
Data were analyzed using GraphPad Prism software version 8.1.1
(GraphPad Software, Inc). Significance difference analyses
between WT PfNF54 and Pf-PvCSP lines were performed using
the unpaired Student’s t-test. The value of p < 0.05 was considered
statistically significant (* p < 0.01, ** p < 0.001, *** p < 0.0001).RESULTS
Generation of Chimeric Plasmodium
falciparum Sporozoites Expressing PfCSP
and Chimeric PvCSP
We have previously shown that chimeric P. falciparum parasites
with the Pfcsp gene replaced by the two major Pvcsp alleles, VK210
and VK247, do not produce salivary gland sporozoites and most
oocysts degenerate before formation of sporozoites (Marin-
Mogollon et al., 2018). It has been shown that viable and
infectious rodent P. berghei sporozoites can be engineered to
express CSP proteins from two different Plasmodium species.
These chimeric sporozoites were generated by introducing a
P. falciparum csp gene as an additional copy into the P. berghei
genome (Mendes et al., 2018a; Mendes et al., 2018b; Reuling et al.,
2020). Based on this observation we aimed at generating chimeric
P. falciparum sporozoites expressing both PfCSP and an chimeric
PvCSP protein (PvCSP-chi). Using CRISPR/Cas9 gene editing, a
chimeric P. falciparum line (Pf-PvCSP) was created that contains
the Pvcsp-chi gene under the control of 967 bp of the Pfcsp gene
promoter region. This expression cassette was introduced into the
neutral Pfp47 locus (PF3D7_1346800) of the genome of
P. falciparum NF54 wild type (WT) parasites. The Pfp47 locus
was selected as it is suitable for introducing transgenes without
compromisingparasite development in the blood and liver stages or
in A. stephensi mosquitoes (Talman et al., 2010; Vaughan et al.,
2012; Vos et al., 2015; Marin-Mogollon et al., 2019; Miyazaki et al.,
2020). The WT PfNF54 parasites were transfected with two
plasmids: a previously described construct containing the Cas9
expression cassettewith the blasticidin (bsd) drug-selectablemarker
cassette (pLf0019) and a donor DNA construct (pLf0109) designed
to target the Pfp47 locus. The donor construct contains the
Pvcsp-chi expression cassette flanked by two homology regions
of Pfp47, the Pfp47 sgRNA sequence and a hdhfr-yfcu drug-
selectable marker cassette (see Figures 1A, S1, S2 andMaterials
and Methods section for details of the generation of the
constructs). This Pvcsp-chi gene contains the N- and C-
terminal regions of the Pvcsp VK210 allele that flank a
chimeric repeat sequence comprising repeats of both the
VK210 allele (three times the repeat GDRADGQPA/
GDRAAGQPA) and the VK247 allele (three times the repeat
ANGAGNQPG/ANGAGDQPG). Transfection of WT PfNF54Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6parasites was performed using the ‘spontaneous uptakemethod’.
Briefly, uninfected RBC were first transfected with the constructs
pLf0019 and pLf0109. Subsequently, the transfected RBCs were
mixed with WT PfNF54 infected RBC (iRBC). Selection of
transfected parasites containing both plasmids was performed by
applying double-positive selection with the drugs Blasticidin and
WR99210 until parasites were detectable by thin blood-smear
analysis. Subsequently negative drug selection with 5-
fluorocytosine was applied to enrich the parasites in which the
Pvcsp-chi gene expression cassette was integrated into the genome
bydoublecross-overhomologous recombination.Nextdrug-selected
parasites were cloned by limiting dilution. Diagnostic (long range)
PCR and Southern analyses of three clones (Pf-PvCSP cl1, cl3, and
cl4) confirmed correct double crossover integration of the Pvcsp-chi
gene expression into the Pfp47 locus in the genome of all Pf-PvCSP
clones (Figures 1B, C). Two Pf-PvCSP clones (cls 1, 3) were selected
for further phenotype characterization.
Pf-PvCSP Parasites Produce Sporozoites
in Anopheles stephensi Mosquitoes
The in vitro growth of Pf-PvCSP (cl3) blood stages was
comparable to that of the parental WT PfNF54 blood stage
parasites (Figure 1D). Pf-PvCSP parasites produced numbers of
mature gametocytes in standardized gametocyte cultures similar
to those of the parental line (Table 1; Figure S3) and male
gametocytes underwent exflagellation upon activation. Using
SMFA, A. stephensi mosquitoes were infected with gametocytes
of either WT PfNF54 or Pf-PvCSP parasites. The number of
oocysts in mosquito midguts was determined at days 10 to 12
after infection and the number of sporozoites in salivary glands
was analyzed at days 18 to 24 after infection. These analyses
revealed that Pf-PvCSP parasites produced comparable number of
oocysts and salivary gland sporozoites to those of the parental
parasites (Table 1; Figures S3 and S4). Approximately 90% of Pf-
PvCSP oocysts already contained sporozoites at days 10 to 12
which is in contrast to the two previously created chimeric
P. falciparum lines with the Pfcsp gene replaced by the Pvcsp
alleles vk210 and vk247. Most of the oocysts of these replacement
lines degenerated before the formation of sporozoites (Marin-
Mogollon et al., 2018). The presence of Pf-PvCSP sporozoites in
salivary glands (Table 1) indicated that PfCSP retains its normal
function in the formation of sporozoites, and that expression of
PvCSP-chi in these sporozoites does not appear to interfere with
sporozoite formation and invasion of salivary glands.
Pf-PvCSP Sporozoites Express PfCSP As
Well As PvCSP-chi on Their Surface
To analyze the expression of PvCSP-chi and PfCSP in salivary
gland sporozoites of the Pf-PvCSP line, we first performed an
immunofluorescence on fixed/permeabilized sporozoites with
antibodies specific for the repeat sequences of either PvCSP
VK210, PvCSP VK247 or PfCSP. All Pf-PvCSP sporozoites
analyzed (n=2 exp.) reacted with all three antibodies whereas
WT PfNF54 sporozoites reacted only with anti-PfCSP antibodies
(Figure 2), indicating that all Pf-PvCSP sporozoites expressed
both the PfCSP and PvCSP-chi proteins.December 2020 | Volume 10 | Article 591046
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the surface of sporozoites, by performing IFA of live salivary gland
sporozoites. Similarly to the results of IFA using fixed/
permeabilized sporozoites, live Pf-PvCSP sporozoites reacted withFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 7anti-PvCSP VK210, anti-PvCSP VK247 and anti-PfCSP antibodies
whereas WT PfNF54 sporozoites reacted only to anti-PfCSP
antibodies (Figure 3A). This result demonstrates that the PvCSP-




FIGURE 1 | Generation and genotyping of the chimeric Pf-PvCSP parasites. A schematic representation of the Cas9 (plasmid Leiden falciparum (pLf) 0019) and
donor DNA plasmids (pLf0109) constructs used to introduce the Pvcsp chimeric (Pvcsp-chi) expression cassette into the PfNF54 p47 gene locus. The Pvcsp-chi
gene contains a chimeric repeat region of VK210 and VK247 alleles and is under the control of the promoter of the Pfcsp gene. The p47 homology regions (HR1,
HR2) used to introduce the donor DNA, location of primers (P), sizes of restriction fragments (HpaI and EcoRI; in red), and PCR amplicons (in black) are indicated.
WT, wild type; bsd, blasticidin selectable marker (bsd); hdhfr::yfcu, in donor plasmid. (B) Diagnostic PCRs confirming the correct integration of the Pvcsp-chi
expression cassette into the Pfp47 locus. Diagnostic PCR: part of Pvcsp-chi open reading frame (primers P4/P5); part of Pfp47 open reading frame (primers P6/P7);
5’-integration of the plasmid into the Pf-PvCSP-chi genome (5’-Int; primers P1/P2); LR-PCR (primers P1/P3). (C) Southern analysis of HpaI and EcoRI restricted
DNA of WT, and chimeric Pf-PvCSP parasites confirms the specific integration of the Pvcsp genes into the Pfp47 gene locus. (D) Growth of asexual blood-stages of
Pf-PvCSP cl3 and WT PfNF54. Parasitemia (mean and S.D of 3 independent cultures) is shown during a 3-day culture period (in the semi-automated culture
system). Cultures were initiated with a parasitemia of 0.1%.December 2020 | Volume 10 | Article 591046
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assessed if PvCSP is also shed similarly to PfCSP by Pf-PvCSP
sporozoites. CSP-trails in a sporozoite gliding assay also reacted
with both anti-PfCSP and anti PvCSP VK210 antibodies (Figure
3B), confirming surface expression of PvCSP-chi and revealing
shedding of PvCSP-chi during gliding. Comparable gliding trails
were observed in WT PfNF54 and Pf-PvCSP sporozoites using
anti-PfCSP antibody (Figure 3B), with a percentage of 85%
gliding trails in WT PfNF54 sporozoites (with a range of 28–65
gliding trails per field, Stdev. 2.6) and 87.0% gliding trails in Pf-
PvCSP sporozoites (with a range of 23–43 gliding trails per field,
Stdev 7,6.).
Pf-PvCSP Sporozoites Infect Primary
Human Hepatocytes
We next assessed the in vitro infectivity of Pf-PvCSP sporozoites
to primary human hepatocytes. At day 4 post infection of
primary human hepatocytes with either WT or Pf-PvCSP
sporozoites, the cells were fixed, and liver stages were stained
with an anti-PfHSP70 antibody. Pf-PvCSP sporozoites showed
comparable efficiency of hepatocyte infection to WT PfNF54
sporozoites (Figure 4). Pf-PvCSP andWT PfNF54 also displayed
similar liver stage sizes at day 4 post infection (Figure 4). These
results demonstrate that expression of PvCSP-chi at the surface
of Pf-PvCSP sporozoites did not reduce parasite in vitro invasion
and development in primary human hepatocytes.
Immunization of Mice with Pf-PvCSP Sporozoites
Induce Antibodies Against Repeats of Both PfCSP
and PvCSP-chi
We then analyzed the capacity of the Pf-PvCSP sporozoites to
elicit the production of antibodies against the repeat sequences of
PfCSP and PvCSP-chi by immunizing mice with killed Pf-PvCSP
and WT PfNF54 sporozoites. Groups of six C57BL/6 mice were
intravenously injected with 105 freeze-thaw killed sporozoites,
three times with a 7-day interval, and blood was collected from
all mice 1 day prior to the first and third immunization andFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 81 week after the last immunization (Figure 5A). Plasma of these
mice was tested for antigen-specific antibody production by
ELISA using plates that were coated with the following repeat
sequences; (NANP)4NVDPC for PfCSP; GD RAD GQP AGD
RAA GQP A for PvCSP VK210; and ANGAGNQPG
ANGAGDQPG for PvCSP VK247 strain.
Plasma samples of mice immunized with either WT PfNF54
or Pf-PvCSP sporozoites reacted strongly to the PfCSP repeat
sequences after the second and third immunization with no
significant differences in total IgG between the two groups of
mice (Figure 5B), indicating comparable immunogenicity of the
PfCSP repeat sequences in WT PfNF54 or Pf-PvCSP sporozoites.
In contrast, only mice immunized with Pf-PvCSP sporozoites
showed significantly increased antibody titers specific for the
repeat sequences of PvCSP VK210 and PvCSP VK247 whereas
no significant increase was observed in WT PfNF54-immunized
mice (Figure 5B). Although the total IgG against the PvCSP
repeats was lower than that against the PfCSP repeats, these
results show that exposure to Pf-PvCSP sporozoites can induce
the production of antibodies against PfCSP, as well as against
both PvCSP repeat variants.DISCUSSION
In this study we describe a chimeric P. falciparum line, Pf-PvCSP,
which expresses CSP from both P. falciparum and P. vivax. We
demonstrate that chimeric parasites produce sporozoites in similar
numbers to those of the parental WT PfNF54 line and that both
CSPs expressed in the chimeric parasites are present at the
sporozoite surface and shed during gliding. Our results show that
Pf-PvCSP sporozoites are infectious to primary human
hepatocytes. These observations support the notion that the
presence of the chimeric PvCSP protein at the surface of P.
falciparum sporozoites does not affect sporozoite viability and
infectivity. The formation of infective sporozoites expressing CSP
of two different Plasmodium species has been previouslyTABLE 1 | Gametocyte, oocyst, and sporozoite production of Pf-PvCSP and WT NF54 lines.
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(Mendes et al., 2018b). However, the viability and infectivity of
these chimeric Pb-PfCSP sporozoites is expected, since PfCSP can
fully complement the multiple functions of PbCSP as shown in
replacement P. berghei lines with the endogenous PbCSP replaced
by PfCSP (Triller et al., 2017; Flores-Garcia et al., 2019). This is
distinct from PvCSP, since previous attempts to functionally
complement PfCSP, by replacing the Pfcsp gene with two Pvcsp
alleles, were unsuccessful (Marin-Mogollon et al., 2018). It is
known that CSP fulfills multiple functions, both in the process of
sporozoite formation and in later processes of sporozoite invasion
of salivary glands,migration through the human skin and invasion
of hepatocytes (Sinnis and Coppi, 2007; Vaughan et al., 2008;
Ejigiri and Sinnis, 2009; Coppi et al., 2011; Vaughan and
Kappe, 2017).
Although the previously generated gene-replacement Pf-PvCSP
parasites were able to produce normal numbers of oocysts, no
salivary gland sporozoitewere formed andmost oocyst degenerated
before sporozoite formation, a phenotype that is comparable to
P. falciparum mutants lacking the Pfcsp gene (Marin-Mogollon
et al., 2018). Collectively, these observations indicate that PvCSP is
unable to fully complement the role of PfCSP in the process of
sporozoite formation inside oocysts but that the simultaneous
expression of PvCSP with PfCSP in sporozoites of chimeric
parasites does not hamper the formation of infectious
sporozoites. The lack of full complementation of PfCSP by PvCSP
in the process of sporozoite formationmay result from the inability
of PvCSP to interact with other P. falciparum proteins that are
involved in (the initial steps of) sporozoite formation.
Our studies of immunization of mice with the chimeric Pf-
PvCSP sporozoites shows that antibodies are induced against the
repeat sequences of both PfCSP and the PvCSP-chi protein,
including antibody responses against both PvCSP alleles, VK210
and VK247. Interestingly, although IgG responses against PfCSP
were significantly higher than against PvCSP, anti- PfCSP titers
were comparable for mice immunized with either WT PfNF54
sporozoites or Pf-PvCSP sporozoites. These observations indicate
that the presence of PvCSP does not affect the immunogenicity of
PfCSP with respect to IgG responses against the NANP/NVDP
repeats. The lower IgG responses against the two PvCSP repeats
compared to the PfCSP NANP/NVDP repeats can be caused by
different factors. The PvCSP-chi protein contains only 3 copies of
the VK247 and VK210 repeats, while the P. falciparum NF54
CSP protein contains 38 NANP and 4 NVDP repeats (Bowman
et al., 1999; Oyen et al., 2018). In addition, although we provide
evidence of the presence of PvCSP at the surface of the Pf-PvCSP
sporozoites and in gliding trails, the total amount of PfCSP and
PvCSP in the Pf-PvCSP sporozoites is unknown and may differ
for the two proteins. The lower IgG responses might also result
from a lower intrinsic immunogenicity of the PvCSP repeats
compared to the P. falciparumNANP/NVDP repeats. The repeat
regions of CSP of the P. vivax strains VK210 and VK247 consist
of 10–11 copies of the repeats GDRA(A/D)GQPA or ANGA (G/
D)(N/D)QPG, respectively (de Souza-Neiras et al., 2007)] and
are not cross reactive (Hall et al., 2019). Of note, our study
employed freeze-thaw killed sporozoites to immunize mice; it isFIGURE 2 | Immunofluorescence analyses of PvCSP and PfCSP expression
in fixed Pf-PvCSP salivary gland sporozoites. Fixed permeabilized sporozoites
of Pf-PvCSP (clone 1 and clone 3) and WT PfNF54 parasites stained with
mouse anti-PvCSPVK210, anti-PvCSP VK247 (green; alexa 488) and anti-
PfCSP antibodies (red; alexa 594). Nuclei stained with the Hoechst-33342.
Control negative, corresponds to the incubation without the primary antibody
(2 experiments). Scale bar is 5 µm.December 2020 | Volume 10 | Article 591046
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PvCSP-chi proteins might be different when immunization is
performed with live sporozoites.
Despite the differences in the repeat regions of P. falciparum
and P. vivax CSP, both these proteins have been shown to beFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 10immunogenic and antibody levels against these repeats appear to
be associated with protective immunity in animal malaria models
and in humans (Porter et al., 2013; Foquet et al., 2014; Schwenk et al.,
2014; Yadava et al., 2014; White et al., 2015; Gimenez et al., 2017;
Atcheson et al., 2018; de Camargo et al., 2018; Dobaño et al., 2019).A
B
FIGURE 3 | Immunofluorescence analyses of PvCSP and PfCSP expression of live Pf-PvCSP salivary gland sporozoites. (A) Live sporozoites of Pf-PvCSP and WT
PfNF54 parasites labelled with mouse anti-PvCSPVK210, anti-PvCSP VK247 and anti-PfCSP antibodies (green; alexa 488). Nuclei stained with the Hoechst-33342.
Control negative, corresponds to the incubation without the primary antibody (2 experiments). Scale bar is 5 µm. (B) Typical sporozoite gliding trails of Pf-PvCSP and
WT PfNF54 sporozoites stained with mouse anti-PvCSPVK210 and anti-PfCSP antibodies (left) and percentage of gliding trials (right) using primary antibody anti-Pf-
3SP2 and anti-PvCSPVK210 (1 experiment). Scale bar is 15 µm. ns, not significant, as determined by One-way ANOVA test (GraphPad).December 2020 | Volume 10 | Article 591046
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analyzing antibody production after immunizationwith full-length
CSP proteins or the respective repeat sequences, the relative
immunogenicity of the PfCSP and PvCSP repeats in both animal
models and in humans is largely unknown. To our knowledge, no
studies exist that have compared the immunogenicity of different
CSP repeat sequences of the two human Plasmodium species using
similar immunization approaches and delivery systems. In
comparative P. vivax and P. falciparum CHMI studies, it has been
found that theCSPofbothspecies inducedcross-reactive antibodies
(Hall et al., 2019). However, it is unknown whether the observed
cross-reactivity resulted from the repeat sequences or from other
epitopes in the N- or C-terminal region of the CSP molecules. In
future studies it will be relevant to analyze infections in the FRG
huHepmousemodel (repopulatedwith humanRBCs) to show that
Pf-PvCSP can form infectious liver merozoites. This would enable
the use of this model for testing the efficacy of anti-
PvCSP antibodies.
Combined, our observations regarding the expression and
immunogenicity of the PvCSP on the surface of P. falciparum
sporozoites hold promise for the use of the chimeric Pf-PvCSP
sporozoites for clinical evaluation of vaccines targeting PvCSP in
clinical CHMI studies. The use of such parasites would bypass the
need for P. vivax sporozoite production and measures for
hypnozoite removal (Payne et al., 2017). In addition, such
chimeric sporozoites might also be used in whole, attenuated
sporozoite vaccination approaches (Bijker et al., 2015; Goswami
et al., 2020). Vaccination with chimeric, attenuated sporozoites
might induce cross-protective immune responses against both
P. falciparum and P. vivax.A
B
FIGURE 5 | Antibody production against repeat sequences of PfCSP and PvCSP-chi in mice after immunization with Pf-PvCSP and WT PfNF54 sporozoites.
(A) Schematic representation of the immunization protocol. Groups of six C57BL/6 mice were immunized three times with killed sporozoites with a 7-day interval and
blood was collected from all mice by orbital vein puncture 1 day before the first and third immunization and one week after the last immunization (one experiment).
(B) Total IgG titers against PfCSP and PvCSP repeat sequences in plasma prior, during and after immunization. Enzyme-linked immunosorbent assays were
performed with plasma samples collected from mice as shown in (A) to assess total IgG titers specific for the repeat sequences of PfCSP ((NANP)4NVDPC) and two
variants of PvCSP(GD RAD GQP AGD RAA GQP A for PvCSP VK210; ANGAGNQPG ANGAGDQPG for the PvCSP VK247. Mean and standard error of the mean
and *p < 0.05; **p < 0.01; ***p < 0.001, as determined by unpaired t-test analysis.A
B
FIGURE 4 | In vitro infection of primary human hepatocytes by Pf-PvCSP
sporozoites. (A) Representative images of liver stage development in primary
human hepatocytes 4 days after infection with Pf-PvCSP and WT PfNF54
sporozoites. Liver stages were stained with anti-PfHSP70 antibodies and
nuclei were stained with DAPI (1 experiment). Scale bar is 10 µm.
(B) Percentage of infected hepatocytes (left) and size of liver stages (right) at
day 4 after infection of hepatocytes by Pf-PvCSP and WT NF54 sporozoites.
The size was measured by determining the area of the parasite cytoplasm
using the red-positive (anti-HSP70) area (µm2). n.s., not significant, as
determined by unpaired t-test (GraphPad).December 2020 | Volume 10 | Article 591046
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SUPPLEMENTARY FIGURE 1 | Plasmid maps of plasmids used in this study.
SUPPLEMENTARY FIGURE 2 | Plasmid map of pLf0109 and sequence of the
commercially synthesized Pvcsp-chi gene. This gene that contains a codon-
optimized Pvcsp open reading frame containing the N- and C-terminal regions of
the Pvcsp VK210 allele that flank a chimeric repeat sequence comprising repeats of
both the VK210 allele (three times the repeat GDRADGQPA/GDRAAGQPA) and the
VK247 allele (three times the repeat ANGAGNQPG/ANGAGDQPG).
SUPPLEMENTARY FIGURE 3 | Percentage of male exflagellating gametocytes
and number of oocyst and sporozoites of Pf-PvCSP cl3 and WT PfNF54 parasites.
(A) Percentage of stage V exflagellating male gametocytes in day 14 gametocyte
cultures (3 experiments). Each dot correspond to an independent experiment.
(B) Number of oocyst per mosquito at day 10 after feeding (n=3). Each dot
correspond to the number of oocysts per midgut. (C) Number of sporozoites per
mosquito at day 18–24 after feeding (n=3). Each dot corresponds to the mean
number of sporozoites per mosquito. Mean and standard error of the mean. n.s.,
not significant (unpaired t-test; Graphpad).
SUPPLEMENTARY FIGURE 4 | Sporozoite formation in oocysts of Pf-PvCSP
and WT PfNF54 parasites. Representative images of oocyst during development
(A) and sporozoite formation (B) in oocysts (day 10) from WT NF54 parasites and
Pf-PvCSP parasites that express both PfCSP and PvCSP-chi. (A) Complete midgut
and magnified area (×5). Scale bar: 200 µm (upper row) and 20 µm (lower row).
(B) Sporozoite formation in an unstained oocyst. Scale bar: 20 µm.
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Amado-Garavito, A. B., Céspedes, N., et al. (2016). Protective Efficacy of
Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian
Volunteers: A Randomized Controlled Trial. PLoS Negl. Trop. Dis. 10,
e0005070. doi: 10.1371/journal.pntd.0005070Atcheson, E., Bauza, K., Salman, A. M., Alves, E., Blight, J., Viveros-Sandoval,
M. E., et al. (2018). Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy
through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
Infect. Immun. 86, 1–16. doi: 10.1128/IAI.00114-18
Bennett, J. W., Yadava, A., Tosh, D., Sattabongkot, J., Komisar, J., Ware, L. A., et al.
(2016). Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate
VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and
Efficacy. PLoS Negl. Trop. Dis. 10, e0004423. doi: 10.1371/journal.pntd.0004423
Bijker, E. M., Borrmann, S., Kappe, S. H., Mordmuller, B., Sack, B. K., and Khan,
S. M. (2015). Novel approaches to whole sporozoite vaccination against
malaria. Vaccine 33, 7462–7468. doi: 10.1016/j.vaccine.2015.09.095
Bijker, E. M., Sauerwein, R. W., and Bijker, W. E. (2016). Controlled human
malaria infection trials: How tandems of trust and control construct scientific
knowledge. Soc. Stud. Sci. 46, 56–86. doi: 10.1177/0306312715619784December 2020 | Volume 10 | Article 591046
Miyazaki et al. Chimeric P. falciparum Expressing P. vivax CSPBowman, S., Lawson, D., Basham, D., Brown, D., Chillingworth, T., Churcher,
C. M., et al. (1999). The complete nucleotide sequence of chromosome 3 of
Plasmodium falciparum. Nature 400, 532–538. doi: 10.1038/22964
Clemens, J., and Moorthy, V. (2016). Implementation of RTS,S/AS01 Malaria
Vaccine–The Need for Further Evidence. N. Engl. J. Med. 374, 2596–2597. doi:
10.1056/NEJMe1606007
Cohen, J., Nussenzweig, V., Nussenzweig, R., Vekemans, J., and Leach, A. (2010).
From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum.
Vaccin. 6, 90–96. doi: 10.4161/hv.6.1.9677
Coppi, A., Natarajan, R., Pradel, G., Bennett, B. L., James, E. R., Roggero, M. A.,
et al. (2011). The malaria circumsporozoite protein has two functional
domains, each with distinct roles as sporozoites journey from mosquito to
mammalian host. J. Exp. Med. 208, 341–356. doi: 10.1084/jem.20101488
de Camargo, T. M., de Freitas, E. O., Gimenez, A. M., Lima, L. C., De Almeida
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